Albert D. Bolles
Dr. Bolles has served as a director since May 2014. Dr. Bolles is a sitting member of the Compensation Committee and the Nominating & Corporate Governance Committee. Dr. Bolles served as Executive Vice President, Chief Technical and Operations Officer at ConAgra Foods until his retirement in August 2015. Dr. Bolles had been with ConAgra Foods, one of North America’s largest packaged food companies, since 2006 and led the Research, Quality & Innovation and Supply Chain organizations. Dr. Bolles has led innovation programs for multiple new products, generating incremental sales and a multi-year pipeline to sustain and advance future growth. In advancing innovation at ConAgra, Dr. Bolles developed two external scientific advisory boards comprised of nationally recognized leaders to shape strategy and create industry leadership for ConAgra in Health & Wellness and Food Safety. As an industry partner with the FDA and USDA on influencing and crafting public policy that benefits consumers, Dr. Bolles was instrumental in the passage of the Food Safety Modernization Act in 2010. Prior to joining ConAgra Foods, Dr. Bolles led worldwide research and development for PepsiCo Beverage and Foods. Dr. Bolles holds six patents and has won numerous awards for his contribution to the world of food science. He is a graduate of Michigan State University with a B.S. in Microbiology plus an M.S. and Ph.D. in Food Science.
Mr. Frank has served as director since December 1999. Currently Mr. Frank is the Chairman of the Nominating & Corporate Governance Committee and a sitting member of the Compensation Committee. Mr. Frank is Chairman of the Board of Evolution Life Science Partners LLC. Prior to joining Evolution Partners, Mr. Frank was Chairman of the Board of Burrill Securities, an investment banking and advisory firm. Prior to joining Burrill Securities, Mr. Frank was Vice Chairman of Peter J. Solomon Company (“Solomon”). Before joining Solomon, Mr. Frank was Vice Chairman of Lehman Brothers, Inc. (“Lehman”) and Barclays Capital. Before joining Lehman as a Partner in October 1969, Mr. Frank was co-director of research, as well as Vice President and Director of Smith Barney & Co. Incorporated. During his over 50 years on Wall Street, Mr. Frank has been involved in numerous financings and merger and acquisition transactions. He serves as an advisor to the board of directors of PDL BioPharma, and was a director for the Institute for Systems Biology and Pharmaceutical Product Development, Inc. Mr. Frank is Chairman of the National Genetics Foundation and he serves on the Advisory Boards for Yale School of Organization and Management, the Massachusetts Institute of Technology Center of Biomedical Innovation and was formerly an Advisory Member of the Johns Hopkins Bloomberg School of Public Health, and the Harvard School of Public Health. He is a graduate of Yale University, received an M.B.A. from Stanford University and is a Chartered Financial Analyst.
Mr. Goldby has served as a director since December 2008. Mr. Goldby is the Chairman of the Board of Directors and the Board’s Outside Lead Independent Director and a sitting member of the Audit Committee. Mr. Goldby has been a Partner at Venrock, a venture capital firm, since 2007. Mr. Goldby was Chairman and Chief Executive Officer of Symyx Technologies, Inc. (“Symyx”) from 1998 to 2007; he became the Executive Chairman in 2008, and Chairman in 2009. Before joining Symyx, Mr. Goldby served as Chief Executive Officer for more than ten years at MDL Information Systems, Inc., the enterprise software company that pioneered scientific information management. Earlier, Mr. Goldby held various management positions at ALZA Corporation, including President of Alza Pharmaceuticals. Mr. Goldby received a B.S. degree in chemistry from the University of North Carolina and a law degree from Georgetown University Law Center.
Ms. Hemmeter was elected to serve as a director effective October 15, 2015, in addition Ms. Hemmeter began to serve as Landec’s President and Chief Executive Officer. Ms. Hemmeter has served as Chief Operating Officer since January 2014, prior to which she served as Chief Commercial Officer of Landec from December 2010 to January 2014 and Vice President, Business Development and Global Marketing for Landec from June 2009 to December 2010. From July 2006 until joining Landec Ms. Hemmeter was Vice President of Global Marketing and New Business Development for the Performance Materials division of Ashland, Inc., a global specialty chemicals company. Prior to joining Ashland, Inc., Ms. Hemmeter held various executive positions at Siterra Corporation, Bausch & Lomb and Eli Lilly & Company. Ms Hemmeter holds BS and MEng degrees in chemical engineering from the University of Louisville and an MBA from Harvard.
Ms. Pankopf has served as a director since November 2012. At this time Ms. Pankopf serves as Chairman of the Audit Committee and a sitting member of the Nominating & Corporate Governance Committee. Ms. Pankopf has been managing partner of Pareto Advisors, LLC since 2005. Previously, she was a senior analyst and managing director at Palladio Capital Management from January 2004 through April 2005. From 2001 to 2003, Ms. Pankopf served as an analyst and portfolio manager with P.A.W. Capital Partners, LP. Ms. Pankopf was a senior analyst and vice president at Goldman, Sachs & Co. from 1999 to 2001 and at Merrill Lynch & Co. from 1998 to 1999. Ms. Pankopf serves on the Board of Directors of TICC Capital Corp. and served on the Board of the University System of Maryland Foundation from 2006 to 2012. Ms. Pankopf is a member of the National Association of Corporate Directors and has been designated an NACD Governance Fellow in recognition of her ongoing involvement in director professionalism and engagement with the director community. Ms. Pankopf received a Bachelor of Arts degree summa cum laude from the University of Maryland and an M.S. degree from the London School of Economics.
Catherine A. Sohn
Dr. Sohn has served as a director since November 2012. Currently, Dr. Sohn serves as Chairman of the Compensation Committee. Dr. Sohn brings significant industry experience in pharmaceutical and consumer health-related sectors based on her leadership and achievements in business development and new product commercialization over 28 years at GlaxoSmithKline (“GSK”). Most recently, Dr. Sohn was Senior Vice President of Worldwide Business Development and Strategic Alliance for GSK’s $8 billion consumer healthcare division. Previously, Dr. Sohn established the U.S. vaccine business unit for SmithKline Beecham Pharmaceuticals and subsequently led the commercialization of one of GSK’s top five largest pharmaceutical products. Dr. Sohn is Dean’s Professor at the University of the Sciences in Philadelphia and concurrently serves on the Dean’s Advisory Council for Drexel University School of Public Health and the Close School of Entrepreneurship, the Ben Franklin Technology Partners Investment Advisory Committee, Springboard Enterprises Life Science Council and was formerly a Member of the Johns Hopkins Bloomberg School of Public Health Advisory Board. Dr. Sohn is a National Association of Corporate Directors (NACD) Governance Fellow and a Certified Licensing Professional. Dr. Sohn received her Doctor of Pharmacy degree from University of California in San Francisco and a Certificate in Professional Development from the Wharton School at the University of Pennsylvania.
Gary T. Steele
Mr. Steele has served as a director since September 1991 and was Chairman of the Board of Directors from January 1996 through October 2015. Mr. Steele retired in 2015 as President and Chief Executive Officer of Landec, a position he held for 24 years. Mr. Steele has over 30 years of experience in the biotechnology, instrumentation and material science fields. From 1985 to 1991, Mr. Steele was President and Chief Executive Officer of Molecular Devices Corporation, a bioanalytical instrumentation company. From 1981 to 1985, Mr. Steele was Vice President, Product Development and Business Development at Genentech, Inc., a biomedical company focusing on pharmaceutical drug development. Mr. Steele has also worked with McKinsey & Company and Shell Oil Company. Mr. Steele received a B.S. from Georgia Institute of Technology and an M.B.A. from Stanford University
Mr. Tobin has served as a director since December 2004. Presently Mr. Tobin is a sitting member of the Audit Committee and the Nominating & Corporate Governance Committee. Mr. Tobin retired from his position as Chief Executive Officer of Ahold USA in 2001. Mr. Tobin has over 40 years of industry experience in the food retail and food service sectors, having served as Chairman and CEO of Stop and Shop Supermarkets. This experience provides the Board of Directors with significant expertise with respect to issues facing the Company’s food business. An industry leader, Mr. Tobin serves on the advisory boards of the College of Agriculture and Life Sciences and the Undergraduate Business Program at Cornell University where he received his B.S. in Agricultural Economics.